Business Context and Reporting Period
Company: TriSalus Life Sciences, Inc. (TLSI)
Filing Type: Form 8-K (Current Report)
Date of Report: June 23, 2025
Event: Commencement of an exchange offer and consent solicitation regarding the Company's Preferred Stock.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The filing text does not provide a clear value for these items.
Capital Structure Details:
- Common Stock Offered: Up to 11,860,206 shares of Common Stock are being offered in exchange for Preferred Stock.
- Exchange Ratio: Preferred Stockholders may receive Common Stock equal to the "Exchanged Value" (Liquidation Preference + Accrued Dividends through August 10, 2027) divided by $4.00.
- Preferred Stock Amendment: If approved, the amendment will allow mandatory conversion of remaining Preferred Stock at a price 11.3% less favorable than the exchange offer ratio.
Material Changes
The primary material change is the initiation of a restructuring of the Company's capital structure through the exchange of Preferred Stock for Common Stock.
- Support Agreements: Parties representing approximately 55% of the outstanding Preferred Stock have agreed to tender their shares and consent to the amendment.
- Regulatory Filings: The Company filed a registration statement on Form S-4 and an exchange offer statement on Schedule TO with the SEC on June 23, 2025.
Guidance, Outlook, and Risks
Outlook and Conditions:
- Expiration Date: The Offer and Consent Solicitation expire at 11:59 p.m. Eastern Standard Time on July 23, 2025, unless extended.
- Withdrawal Rights: Holders may withdraw tendered shares at any time prior to the Expiration Date.
- Management Commentary: The Company anticipates that the Preferred Stock Amendment will be adopted if conditions are satisfied, given the 55% support already secured.
Risks and Contingencies:
- Success depends on the number of holders approving the Preferred Stock Amendment.
- Timing and results of the SEC review of the Form S-4 registration statement.
- General business risks including market conditions, customer acquisition, and competition (referenced from Form 10-Q and Form S-4).
- Forward-looking statements are subject to uncertainties and actual results may differ materially.
Investor Verification Checklist
- Verify the final terms of the exchange offer in the filed Prospectus/Offer to Exchange (Form S-4) and Schedule TO.
- Confirm the total number of Preferred Stock shares tendered and the final percentage of approval for the Preferred Stock Amendment.
- Monitor the SEC's review status of the Form S-4 registration statement filed on June 23, 2025.
- Review the specific calculation of "Accrued Dividends" and "Liquidation Preference" to understand the exact share count to be issued.
- Check for any extensions to the July 23, 2025 Expiration Date.